» Articles » PMID: 34768935

OCT1 Is a Poor Prognostic Factor for Breast Cancer Patients and Promotes Cell Proliferation Via Inducing NCAPH

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Nov 13
PMID 34768935
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Octamer transcription factor 1 (OCT1) is a transcriptional factor reported to be a poor prognostic factor in various cancers. However, the clinical value of OCT1 in breast cancer is not fully understood. In the present study, an immunohistochemical study of OCT1 protein was performed using estrogen receptor (ER)-positive breast cancer tissues from 108 patients. Positive OCT1 immunoreactivity (IR) was associated with the shorter disease-free survival (DFS) of patients ( = 0.019). Knockdown of OCT1 inhibited cell proliferation in MCF-7 breast cancer cells as well as its derivative long-term estrogen-deprived (LTED) cells. On the other hand, the overexpression of OCT1 promoted cell proliferation in MCF-7 cells. Using microarray analysis, we identified the non-structural maintenance of chromosomes condensin I complex subunit H (NCAPH) as a novel OCT1-taget gene in MCF-7 cells. Immunohistochemical analysis showed that IR was significantly positively associated with OCT1 IR ( < 0.001) and that positive IR was significantly related to the poor DFS rate of patients ( = 0.041). The knockdown of inhibited cell proliferation in MCF-7 and LTED cells. These results demonstrate that OCT1 and its target gene are poor prognostic factors and potential therapeutic targets for patients with ER-positive breast cancer.

Citing Articles

Scutellarein treats neuroblastoma by regulating the expression of multiple targets.

Zhai C, Fan J, Zhang R Ibrain. 2024; 10(3):345-355.

PMID: 39346787 PMC: 11427791. DOI: 10.1002/ibra.12100.


Induction of Invasive Basal Phenotype in Triple-Negative Breast Cancers by Long Noncoding RNA BORG.

Niazi F, Parker K, Mason S, Singh S, Schiemann W, Valadkhan S Cancers (Basel). 2024; 16(18).

PMID: 39335212 PMC: 11430157. DOI: 10.3390/cancers16183241.


NCAPH, ubiquitinated by TRIM21, promotes cell proliferation by inhibiting autophagy of cervical cancer through AKT/mTOR dependent signaling.

Wang S, Qiao X, Cui Y, Liu L, Cooper T, Hu Y Cell Death Dis. 2024; 15(8):565.

PMID: 39103348 PMC: 11300717. DOI: 10.1038/s41419-024-06932-y.


THOC7-AS1/OCT1/FSTL1 axis promotes EMT and serves as a therapeutic target in cutaneous squamous cell carcinoma.

Yu S, Cui X, Zhou S, Li Y, Feng W, Zhang X J Transl Med. 2024; 22(1):347.

PMID: 38605354 PMC: 11010364. DOI: 10.1186/s12967-024-05116-8.


NCAPH serves as a prognostic factor and promotes the tumor progression in glioma through PI3K/AKT signaling pathway.

Liang J, Yun D, Jin W, Fan J, Wang X, Wang X Mol Cell Biochem. 2024; 480(1):589-605.

PMID: 38587786 PMC: 11695388. DOI: 10.1007/s11010-024-04976-4.


References
1.
Obinata D, Takayama K, Urano T, Murata T, Kumagai J, Fujimura T . Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer. 2011; 130(5):1021-8. DOI: 10.1002/ijc.26043. View

2.
Wang Y, Jin T, Dai X, Xu J . Lentivirus-mediated knockdown of CEP55 suppresses cell proliferation of breast cancer cells. Biosci Trends. 2016; 10(1):67-73. DOI: 10.5582/bst.2016.01010. View

3.
Shah K, Wilson E, Malla R, Elford H, Faridi J . Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer. Mol Cancer Ther. 2015; 14(11):2411-21. DOI: 10.1158/1535-7163.MCT-14-0689. View

4.
Obinata D, Takayama K, Fujiwara K, Suzuki T, Tsutsumi S, Fukuda N . Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth. Oncogene. 2016; 35(49):6350-6358. DOI: 10.1038/onc.2016.171. View

5.
Zhang X, Wang H, Han Y, Zhu M, Song Z, Zhan D . Induces Cell Proliferation in Cardia Adenocarcinoma via PI3K/AKT Signaling Pathway. Onco Targets Ther. 2020; 13:11315-11326. PMC: 7649252. DOI: 10.2147/OTT.S276868. View